Research Index
Tirzepatide Research Index
PSI surfaces 50 peer-reviewed studies on Tirzepatide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.
Ito H, I C, Matsushita M et al.
Intern Med·2026·Human·PubMed →
Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.
Caputo C
JCEM Case Rep·2026·Human·PubMed →
[Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity].
Blanco Anesto J, Dotres Fallat KM, Nicolau J
Nutr Hosp·2026·Human·PubMed →
Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials.
de Paulo RS, Bonifácio DB, de Carvalho MHL et al.
Diabetes Obes Metab·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.
Shah J, Makwana B, Panchal K et al.
Am J Ophthalmol·2026·Human·PubMed →
LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
Alawadhi AA, Alroudhan D, Alsaeed DJ et al.
BMJ Open·2026·Human·Weight Loss, Glycemic Control·PubMed →
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Johansson E, Wilding JPH, Upadhyay N et al.
J Med Econ·2026·Human·Weight Loss, Glycemic Control·PubMed →
Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.
Velusamy B, Sokumbi O, Latimer BL et al.
JAAD Case Rep·2026·Human·PubMed →
A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications.
Jordan B, Arbogast L, Clemens M et al.
Expert Opin Drug Saf·2026·Human·PubMed →
Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.
Neptune Rosa JM, Oquendo BR, De La Torre Lugo E
JAAD Case Rep·2026·Human·PubMed →
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.
Galindo RJ, Aronne LJ, Horn DB et al.
J Endocrinol Invest·2026·Human·PubMed →
Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.
Thirugnanam AM, Chandrakanth, Pruthvi
Cardiovasc Revasc Med·2026·Human·PubMed →
Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.
Palmisano T, Roeschenthaler P, Passerini H et al.
Eur J Clin Nutr·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.
Kassab J, Drazner MH, Thibodeau JT
ESC Heart Fail·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.
Kutler RB, Lin A, Zhang L et al.
Otolaryngol Head Neck Surg·2026·Human·PubMed →
Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Qazi S, Dawar Zahid M, Atif E et al.
Healthcare (Basel)·2026·Human·PubMed →
Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.
Huang L, Lee A, Kim D et al.
J Am Pharm Assoc (2003)·2026·Human·PubMed →
Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.
Bajaj HS, Billings LK, Sharma P et al.
Diabetes Ther·2026·Human·PubMed →
Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.
Lin PY, Zeng BS, Chen JJ et al.
J Hematol Oncol·2026·Human·PubMed →
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.
Shloush M, Rodriguez V, Guillen V et al.
Arch Endocrinol Metab·2026·Human·PubMed →
Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.
Bruno A, Schirosi M, Foti R
Aesthetic Plast Surg·2026·Human·PubMed →
Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.
Maruyama F, Kitsunai H, Kitao N et al.
Diabetes Obes Metab·2026·Human·PubMed →
Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?
Azeem S, Bulushi LA, Sabt BI
Oman J Ophthalmol·2026·Human·PubMed →
Tirzepatide and metformin effects on hunger and BMI in an adolescent with hyperphagia and severe obesity due to MC4R Deficiency: a case report.
van der Walle EEPL, Boon MR, van Rossum EFC et al.
Obes Facts·2026·Human·PubMed →
Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity.
Takizawa H, Tsuda A, Suriki H et al.
Endocrinol Diabetes Metab Case Rep·2026·Human·PubMed →
Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A critical appraisal.
Corrao S
J Diabetes Investig·2026·Human·PubMed →
Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
Violante-Ortiz R, Rose L, Sharma P et al.
BMJ Open Diabetes Res Care·2026·Human·Glycemic Control·PubMed →
Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.
Boye KS, Sharma P, Chivukula KK et al.
Ann Intern Med·2026·Human·PubMed →
GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.
Musa EYA, Musa AYA
BMC Cardiovasc Disord·2026·Human·PubMed →
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
Nissen SE, Wolski K, D'Alessio D et al.
JAMA Cardiol·2026·Human·PubMed →
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.
Barenbaum SR, Gonzalez A, Verzani Z et al.
Obesity (Silver Spring)·2026·Human·PubMed →
The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.
Sillassen CDB, Faltermeier P, Bjerg JL et al.
BMC Med·2026·Human·PubMed →
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
Galindo RJ, Gudzune KA, Look M et al.
JAMA Netw Open·2026·Human·Weight Loss·PubMed →
Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.
Soliman A, Hamour B, Hammad A et al.
J Diabetes Metab Disord·2026·Human·PubMed →
Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.
Mazzeo A, Alaimo V, Grimaldi LM
Neurol Sci·2026·Human·PubMed →
Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.
Yang SI, Kim SW, Son KH et al.
Nat Commun·2026·Human·PubMed →
Forword for efficacy and safety of tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Leikin JB
Dis Mon·2026·Human·PubMed →
Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Sebastian SA, Ayyalu T, Bimal T et al.
Dis Mon·2026·Human·Weight Loss·PubMed →
Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.
Mortada I, Lee AW, Quach V et al.
Am J Cardiol·2026·Human·PubMed →
Euglycemic diabetic ketoacidosis following treatment with tirzepatide and SGLT-2 inhibitors: A case report and literature review.
Sawamura T, Karashima S, Ohmori A et al.
Intern Med·2026·Human·PubMed →
Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report.
Minoda Y, Ikeda S, Inukai K et al.
Int J Emerg Med·2026·Human·PubMed →
ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.
Zheng Z, Pettus JH, Warner A et al.
Mol Metab·2026·Human·Weight Loss·PubMed →
Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
Ciudin A, Sapin H, Fan L et al.
Adv Ther·2026·Human·PubMed →
Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.
Mondoh A, Contreras F, Craig H et al.
Obes Pillars·2026·Human·PubMed →
Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.
Gougol A, Kwo P, Pike W et al.
Aliment Pharmacol Ther·2026·Human·PubMed →
Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.
Goodman W, Pandher K, Ayub M
JAAD Case Rep·2026·Animal·PubMed →
Data-driven prioritization of high-risk individuals for weight loss interventions.
Demircan K, Carrasco-Zanini J, Williamson A et al.
Nat Med·2026·Animal·PubMed →
National trends in prescription drug expenditures and projections for 2026.
Tichy EM, Rim MH, Tadrous M et al.
Am J Health Syst Pharm·2026·Animal·PubMed →
Use of semaglutide and tirzepatide among people with multiple sclerosis.
Salter A, Novak A, Lancia S et al.
Mult Scler·2026·Animal·PubMed →
Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.
Chen C, Ying Z, Tang Q et al.
Life Metab·2025·Animal·PubMed →